Attached files

file filename
8-K - FORM 8-K - ATHENAHEALTH INCd302119d8k.htm
EX-99.2 - EX - 99.2 - ATHENAHEALTH INCd302119dex992.htm

Exhibit 99.1

athenahealth, Inc. Reports Fourth Quarter and Full Year 2011 Results

 

   

33% Revenue Growth Over Fourth Quarter of 2010

 

   

GAAP Net Income of $5.3 Million, or $0.15 Per Diluted Share

 

   

Non-GAAP Adjusted Net Income of $9.3 Million, or $0.26 Per Diluted Share

WATERTOWN, MA – February 15, 2012 - athenahealth, Inc. (NASDAQ: ATHN) (the “Company”), a leading provider of cloud-based practice management, electronic health record (EHR), and care coordination services to medical groups, today announced financial and operational results for the fourth quarter and full year 2011. The Company will conduct a conference call tomorrow, Thursday, February 16, 2012, at 8:00 a.m. Eastern Time to discuss these results and management’s outlook for future financial and operational performance.

Total revenue for the three months ended December 31, 2011, was $92.5 million, compared to $69.4 million in the same period last year, an increase of 33%. Full year 2011 revenue was $324.1 million, compared to full year 2010 revenue of $245.5 million, an increase of 32%.

“During 2011, athenahealth gained a new set of game stakes in our ongoing effort to build a national health information backbone. With the advent of athenaCoordinator and permission from the government to form a two-sided market for health information exchange, this new service platform positions athenahealth to create a healthy, sustainable market for health information exchange and the beginning of a market for improving the quality of care,” said Jonathan Bush, the Company’s Chairman, President, and Chief Executive Officer. “We have everything we need to incubate health care’s first high-security social network.”

Bush continued, “Meanwhile, our core business kept true to our mission of becoming medical care givers’ most trusted service. We turned in great numbers, increased our credibility with our clients through Meaningful Use and ANSI 5010 preparation, and were gratified with excellent client satisfaction and top KLAS rankings for our athenaCollector and athenaClinicals service offerings. We remain focused on differentiating our service offerings from the legacy software model and will be expanding the swath of work we do for our clients. We have a lot to execute on during 2012, and the athenahealth team is already marching forward.”

For the three months ended December 31, 2011, Non-GAAP Adjusted Gross Margin was 64.2%, down from 66.3% in the same period last year. Non-GAAP Adjusted EBITDA increased slightly to $20.7 million, or 22.4% of total revenue, from Non-GAAP Adjusted EBITDA of $20.2 million, or 29.1% of total revenue, in the same period last year. For the three months ended December 31, 2011, GAAP net income was $5.3 million, or $0.15 per diluted share, and Non-GAAP Adjusted Net Income was $9.3 million, or $0.26 per diluted share. See “Use of Non-GAAP Financial Measures” below.

“We delivered strong top line and bottom line results during 2011 and exceeded our internal goals across the board,” said Tim Adams, the Company’s Chief Financial Officer. “We achieved over 30% revenue growth for the 12th year in a row and increased our installed base across all of our existing service offerings. As we look forward to 2012, we will invest in both growth and innovation in order to continue our 30% growth trajectory and to capitalize on our unique market position.”

For the year ended December 31, 2011, Non-GAAP Adjusted Gross Margin was 63.8%, up from 62.4% for full year 2010. Non-GAAP Adjusted EBITDA grew to $70.6 million, or 21.8% of total revenue, from Non-GAAP Adjusted EBITDA for 2010 of $51.0 million, or 20.8% of total revenue. For full year 2011,

 

1


GAAP net income was $19.0 million, or $0.53 per diluted share. Non-GAAP Adjusted Net Income for the year was $31.8 million, or $0.88 per diluted share. See “Use of Non-GAAP Financial Measures” below.

Key metrics and milestones in the fourth quarter and full year 2011 included the following:

 

   

$2.0 billion in collections posted to client accounts in the fourth quarter of 2011, compared to $1.6 billion in the same quarter of 2010

 

   

$7.3 billion in collections posted to client accounts in all of 2011, compared to $5.9 billion in all of 2010

 

   

38.9 average client Days in Accounts Receivable (DAR) in the fourth quarter of 2011, compared to 38.8 average client DAR in the same quarter of 2010

 

   

32,740 active medical providers using athenaCollector® at December 31, 2011, 23,210 of whom were physicians, compared to 27,114 providers and 19,197 physicians at December 31, 2010

 

   

6,525 active medical providers using athenaClinicals® at December 31, 2011, 4,662 of whom were physicians, compared to 3,348 providers and 2,383 physicians at December 31, 2010

 

   

5,830 active medical providers using athenaCommunicator® at December 31, 2011, 4,098 of whom were physicians, compared to 1,213 providers and 736 physicians at December 31, 2010

As of December 31, 2011, the Company had cash, cash equivalents, and available-for-sale investments of $138.5 million. The Company does not have any outstanding debt obligations.

Use of Non-GAAP Financial Measures

In the Company’s earnings releases, conference calls, slide presentations, and webcasts, the Company may use or discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. The Company’s earnings press releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s web site at http://www.athenahealth.com.

Conference Call Information

To participate in the Company’s live conference call and webcast, please dial 800-446-2782 (or 847-413-3235 for international calls) using conference code No. 31557729, or visit the Investors section of the Company’s web site at www.athenahealth.com. A replay will be available for one week following the conference call at 888-843-7419 (and 630-652-3042 for international calls) using conference code No. 31557729. A webcast replay will also be archived on the Company’s website.

About athenahealth

athenahealth, Inc. is a leading provider of cloud-based business services for physician practices. athenahealth’s service offerings are based on proprietary web-native practice management and electronic health record (EHR) software, a continuously updated payer knowledge-base, integrated back-office service operations, and care coordination services. For more information, please visit http://www.athenahealth.com/ or call (888) 652-8200.

 

2


Forward-Looking Statements

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements reflecting management’s expectations for future financial and operational performance, growth, and business outlook; statements regarding the benefits of the Company’s service offerings, the creation of a sustainable market for health information exchange and a social network for health care, the security of the Company’s services, the expansion of the types of tasks the Company performs for its clients, and the Company’s continued investment in growth and development; and statements found under the Company’s Reconciliation of Non-GAAP Financial Measures section of this release. The forward-looking statements in this release do not constitute guarantees of future performance. These statements are neither promises nor guarantees, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: the Company’s fluctuating operating results; the Company’s variable sales and implementation cycles, which may result in fluctuations in its quarterly results; risks associated with the acquisition and integration of companies and new technologies, including those related to the Company’s ability to successfully integrate the athenaCoordinator SM service and successfully scale the Proxsys services and technologies to achieve expected synergies; risks associated with its expectations regarding its ability to maintain profitability; the impact of increased sales and marketing expenditures, including whether increased expansion in revenues is attained and whether impact on margins and profitability is longer term than expected; changes in tax rates or exposure to additional tax liabilities; the highly competitive industry in which the Company operates and the relative immaturity of the market for its service offerings; and the evolving and complex governmental and regulatory compliance environment in which the Company and its clients operate. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances, or otherwise. For additional disclosure regarding these and other risks faced by the Company, see the disclosures contained in its public filings with the Securities and Exchange Commission, available on the Investors section of the Company’s website at http://www.athenahealth.com and on the SEC’s website at http://www.sec.gov.

Contacts:

Dana Quattrochi (Investors)

Director, Investor Relations

athenahealth, Inc.

(617) 402-1329

investorrelations@athenahealth.com

John Hallock (Media)

Director, Corporate Communications

athenahealth, Inc.

(617) 402-1428

media@athenahealth.com

 

3


athenahealth, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, in thousands, except per share amounts)

 

     December 31,
2011
    December 31,
2010
 

Assets

    

Current assets:

    

Cash and cash equivalents

   $ 57,781      $ 35,944   

Short-term investments

     62,084        80,231   

Accounts receivable - net

     49,038        36,870   

Deferred tax assets

     5,245        3,856   

Prepaid expenses and other current assets

     8,988        6,749   
  

 

 

   

 

 

 

Total current assets

     183,136        163,650   

Property and equipment - net

     52,275        31,899   

Restricted cash

     5,007        8,691   

Software development costs - net

     6,974        3,642   

Purchased intangibles - net

     20,052        12,651   

Goodwill

     47,307        22,450   

Deferred tax assets

     12,532        10,959   

Investments and other assets

     21,503        7,228   
  

 

 

   

 

 

 

Total assets

   $ 348,786      $ 261,170   
  

 

 

   

 

 

 

Liabilities & Stockholders’ Equity

    

Current liabilities:

    

Current portion of long-term debt and capital lease obligations

   $ —        $ 2,909   

Accounts payable

     6,318        559   

Accrued compensation

     28,176        19,178   

Accrued expenses

     17,774        10,981   

Current portion of deferred revenue

     6,345        4,978   

Interest rate derivative liability

     —          490   

Current portion of deferred rent

     960        1,497   
  

 

 

   

 

 

 

Total current liabilities

     59,573        40,592   

Deferred rent, net of current portion

     2,932        5,960   

Deferred revenue, net of current portion

     44,281        35,661   

Other long-term liabilities

     5,529        1,897   

Debt and capital lease obligations, net of current portion

     —          6,307   
  

 

 

   

 

 

 

Total liabilities

     112,315        90,417   

Stockholders’ equity:

    

Preferred stock, $0.01 par value: 5,000 shares authorized; no shares issued and outstanding at December 31, 2011 and 2010, respectively

     —          —     

Common stock, $0.01 par value: 125,000 shares authorized; 36,678 shares issued, and 35,400 shares outstanding at December 31, 2011 35,808 shares issued and 34,530 shares outstanding at December 31, 2010

     367        358   

Additional paid-in capital

     247,131        200,339   

Treasury stock, at cost, 1,278 shares

     (1,200     (1,200

Accumulated other comprehensive (loss) income

     (101     28   

Accumulated deficit

     (9,726     (28,772
  

 

 

   

 

 

 

Total stockholders’ equity

     236,471        170,753   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 348,786      $ 261,170   
  

 

 

   

 

 

 

 

4


athenahealth, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except per share amounts)

 

     Three Months Ended
December 31,
    Twelve Months Ended
December 31,
 
     2011     2010     2011     2010  

Revenue:

        

Business services

   $ 89,293      $ 67,094      $ 312,768      $ 237,145   

Implementation and other

     3,219        2,272        11,299        8,393   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     92,512        69,366        324,067        245,538   
  

 

 

   

 

 

   

 

 

   

 

 

 

Expense:

        

Direct operating

     34,810        24,419        122,795        96,582   

Selling and marketing

     23,235        14,689        79,775        52,675   

Research and development

     6,957        4,905        23,343        18,448   

General and administrative

     13,405        9,649        48,711        43,119   

Depreciation and amortization

     4,826        3,171        16,710        11,117   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total expense

     83,233        56,833        291,334        221,941   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating income

     9,279        12,533        32,733        23,597   

Other income (expense):

        

Interest income

     96        90        396        309   

Interest expense

     (77     (316     (314     (753

Gain (loss) on interest rate derivative contract

     —          276        (73     (199

Other income

     30        50        138        146   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income (expense)

     49        100        147        (497
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes

     9,328        12,633        32,880        23,100   

Income tax provision

     (3,999     (5,330     (13,834     (10,396
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

   $ 5,329      $ 7,303      $ 19,046      $ 12,704   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income per share - Basic

   $ 0.15      $ 0.21      $ 0.54      $ 0.37   

Net income per share - Diluted

   $ 0.15      $ 0.21      $ 0.53      $ 0.36   

Weighted average shares used in computing net income per share:

        

Basic

     35,392        34,419        35,046        34,181   

Diluted

     36,492        35,278        36,050        35,204   

 

5


athenahealth, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

 

     Years Ended December 31,  
     2011     2010  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net income

   $ 19,046      $ 12,704   

Adjustments to reconcile net income to net cash provided by operating activities:

    

Depreciation and amortization

     19,030        12,956   

Amortization of premiums on investments

     1,579        1,152   

Provision for uncollectible accounts

     1,122        1,772   

Deferred income taxes

     (2,962     1,013   

Excess tax benefit from stock-based awards

     (14,208     (9,245

Stock-based compensation expense

     18,901        14,477   

Increase (decrease) in fair value of contingent consideration

     40        (250

Loss on interest rate derivative contract

     73        199   

Changes in operating assets and liabilities:

    

Accounts receivable

     (12,130     (5,319

Prepaid expenses and other current assets

     11,787        5,461   

Other long-term assets

     489        (243

Accounts payable

     688        (1,024

Accrued expenses

     10,887        4,425   

Deferred revenue

     9,987        7,917   

Deferred rent

     (3,565     (1,275
  

 

 

   

 

 

 

Net cash provided by operating activities

     60,764        44,720   
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Capitalized software development costs

     (7,779     (3,881

Purchases of property and equipment

     (16,696     (15,932

Proceeds from sales and disposals of property and equipment

     —          363   

Proceeds from sales and maturities of investments

     168,083        110,741   

Purchases of short term and long-term investments

     (165,657     (145,443

Payments for acquisitions

     (34,882     —     

Change in restricted cash

     3,684        525   
  

 

 

   

 

 

 

Net cash used in investing activities

     (53,247     (53,627
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Proceeds from issuance of common stock under stock plans

     14,097        8,606   

Excess tax benefit from stock-based awards

     14,208        9,245   

Payment of contingent consideration accrued at acquisition date

     (3,355     (195

Financing fee for line of credit

     (741     —     

Payment to terminate interest rate derivative contract

     (563     —     

Payments on long term debt and capital lease obligations

     (9,216     (3,535
  

 

 

   

 

 

 

Net cash provided by financing activities

     14,430        14,121   
  

 

 

   

 

 

 

Effects of exchange rate changes on cash and cash equivalents

     (110     204   
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

     21,837        5,418   

Cash and cash equivalents at beginning of year

     35,944        30,526   
  

 

 

   

 

 

 

Cash and cash equivalents at end of year

   $ 57,781      $ 35,944   
  

 

 

   

 

 

 

Non-cash transactions

    

Property and equipment recorded in accounts payable and accrued expenses

   $ 8,066      $ 214   
  

 

 

   

 

 

 

Tax benefit recorded in prepaid expenses and other current assets

   $ 13,803      $ 7,547   
  

 

 

   

 

 

 

Fair value of Contingent Consideration at acquisition date

   $ 6,836      $ —     
  

 

 

   

 

 

 

Property and equipment acquired under capital leases

   $ —        $ 363   
  

 

 

   

 

 

 

Additional disclosures

    

Cash paid for interest

   $ 183      $ 873   
  

 

 

   

 

 

 

Cash paid for taxes

   $ 2,708      $ 1,636   
  

 

 

   

 

 

 

 

6


athenahealth, Inc.

STOCK-BASED COMPENSATION EXPENSE

(Unaudited, in thousands)

Set forth below is a breakout of stock-based compensation expense for the three and twelve months ended December 31, 2011 and 2010:

 

      Three months ended December 31,      Twelve months ended December 31,  

Stock-based compensation expense charged to:

   2011      2010      2011      2010  

Direct operating

   $ 948       $ 577       $ 3,173       $ 2,298   

Selling and marketing

     1,721         969         5,645         3,509   

Research and development

     815         542         2,311         2,014   

General and administrative

     2,385         1,934         7,772         6,656   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 5,869       $ 4,022       $ 18,901       $ 14,477   
  

 

 

    

 

 

    

 

 

    

 

 

 

athenahealth, Inc.

CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE INVESTMENTS

(Unaudited, in thousands)

Set forth below is a breakout of total cash, cash equivalents, and available-for-sale investments as of December 31, 2011 and 2010:

 

      December 31,
2011
     December 31,
2010
 

Cash, cash equivalents

   $ 57,781       $ 35,944   

Short-term investments

     62,084         80,231   

Long-term investments*

     18,619         5,592   
  

 

 

    

 

 

 

Total

   $ 138,484       $ 121,767   
  

 

 

    

 

 

 

 

* In 2010, the Company began purchasing certain available-for-sale investments that had a maturity date longer than one-year, which it classifies in investments and other assets on the consolidated balance sheet.

 

7


athenahealth, Inc.

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

TO COMPARABLE GAAP MEASURES

(Unaudited, in thousands, except per share amounts)

The following is a reconciliation of the non-GAAP financial measures used by the Company to describe the Company’s financial results determined in accordance with accounting principles generally accepted in the United States of America (GAAP). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”

While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of the Company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP.

Please note that these figures may not sum exactly due to rounding.

Non-GAAP Adjusted Gross Margin

Set forth below is a presentation of the Company’s “Non-GAAP Adjusted Gross Profit” and “Non-GAAP Adjusted Gross Margin,” which represents Non-GAAP Adjusted Gross Profit as a percentage of total revenue.

 

(unaudited, in thousands)    Three Months Ended
December 31
    Twelve Months Ended
December 31
 
   2011     2010     2011     2010  

Total revenue

   $ 92,512      $ 69,366      $ 324,067      $ 245,538   

Direct operating expense

     34,810        24,419        122,795        96,582   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue less direct operating expense

     57,702        44,947        201,272        148,956   

Add: Stock-based compensation expense allocated to direct operating expense

     948        577        3,173        2,298   

Add: Amortization of purchased intangibles

     761        460        2,230        1,840   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted Gross Profit

   $ 59,411      $ 45,984      $ 206,675      $ 153,094   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted Gross Margin

     64.2     66.3     63.8     62.4

 

8


Non-GAAP Adjusted EBITDA

Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted EBITDA” and “Non-GAAP Adjusted EBITDA Margin,” which represents Non-GAAP Adjusted EBITDA as a percentage of total revenue.

 

     Three Months Ended
December 31
    Twelve Months Ended
December 31
 
(unaudited, in thousands)    2011     2010     2011     2010  

Total revenue

   $ 92,512      $ 69,366      $ 324,067      $ 245,538   

GAAP net income

     5,329        7,303        19,046        12,704   

Add: Provision for income taxes

     3,999        5,330        13,834        10,396   

Add: Total other (income) expense

     (49     (100     (147     497   

Add: Stock-based compensation expense

     5,869        4,022        18,901        14,477   

Add: Depreciation and amortization

     4,826        3,171        16,710        11,117   

Add: Amortization of purchased intangibles

     761        460        2,230        1,840   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted EBITDA

   $ 20,735      $ 20,186      $ 70,574      $ 51,031   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted EBITDA Margin

     22.4     29.1     21.8     20.8

Non-GAAP Adjusted Operating Income

Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted Operating Income” and “Non-GAAP Adjusted Operating Income Margin,” which represents Non-GAAP Adjusted Operating Income as a percentage of total revenue.

 

     Three Months Ended
December 31
    Twelve Months Ended
December 31
 
(unaudited, in thousands)    2011     2010     2011     2010  

Total revenue

   $ 92,512      $ 69,366      $ 324,067      $ 245,238   

GAAP net income

     5,329        7,303        19,046        12,704   

Add: Provision for income taxes

     3,999        5,330        13,834        10,396   

Add: Total other (income) expense

     (49     (100     (147     497   

Add: Stock-based compensation expense

     5,869        4,022        18,901        14,477   

Add: Amortization of purchased intangibles

     761        460        2,230        1,840   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted Operating Income

   $ 15,909      $ 17,015      $ 53,864      $ 39,914   
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted Operating Income Margin

     17.2     24.5     16.6     16.3

 

9


Non-GAAP Adjusted Net Income

Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted Net Income” and “Non-GAAP Adjusted Net Income per Diluted Share.”

 

     Three Months Ended
December 31
    Twelve Months Ended
December 31
 
(unaudited, in thousands except per share amounts)    2011     2010     2011     2010  

GAAP net income

   $ 5,329      $ 7,303      $ 19,046      $ 12,704   

Add: (Gain) loss on interest rate derivative contract

     —          (276     73        199   

Add: Stock-based compensation expense

     5,869        4,022        18,901        14,477   

Add: Amortization of purchased intangibles

     761        460        2,230        1,840   
  

 

 

   

 

 

   

 

 

   

 

 

 

Sub-total of tax deductible items

     6,630        4,206        21,204        16,516   

(Less): Tax impact of tax deductible items (1)

     (2,652     (1,682     (8,482     (6,606
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted Net Income

   $ 9,307      $ 9,827      $ 31,768      $ 22,614   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares - diluted

     36,492        35,278        36,050        35,204   

Non-GAAP Adjusted Net Income per Diluted Share

   $ 0.26      $ 0.28      $ 0.88      $ 0.64   

(1) - Tax impact calculated using a statutory tax rate of 40%

 

     Three Months Ended
December 31
    Twelve Months Ended
December 31
 
(unaudited, in thousands except per share amounts)    2011     2010     2011     2010  

GAAP net income per share - diluted

   $ 0.15      $ 0.21      $ 0.53      $ 0.36   

Add: (Gain) loss on interest rate derivative contract

     —          (0.01     0.00        0.01   

Add: Stock-based compensation expense

     0.16        0.12        0.52        0.41   

Add: Amortization of purchased intangibles

     0.02        0.01        0.06        0.05   
  

 

 

   

 

 

   

 

 

   

 

 

 

Sub-total of tax deductible items

     0.18        0.12        0.59        0.47   

(Less): Tax impact of tax deductible items (1)

     (0.07     (0.05     (0.24     (0.19
  

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP Adjusted Net Income per Diluted Share

   $ 0.26      $ 0.28      $ 0.88      $ 0.64   
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares - diluted

     36,492        35,278        36,050        35,204   

(1) - Tax impact calculated using a statutory tax rate of 40%

 

10


Explanation of Non-GAAP Financial Measures

The Company reports its financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand the Company’s short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company’s ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company’s ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company’s financial and operational performance and comparing this performance to its peers and competitors.

Management defines “Non-GAAP Adjusted Gross Profit” as total revenue, less direct operating expense, plus (1) stock-based compensation expense allocated to direct operating expense and (2) amortization of purchased intangibles, and “Non-GAAP Adjusted Gross Margin” as Non-GAAP Adjusted Gross Profit as a percentage of total revenue. Management considers these non-GAAP financial measures to be important indicators of the Company’s operational strength and performance of its business and a good measure of its historical operating trends. Moreover, management believes that these measures enable investors and financial analysts to closely monitor and understand changes in the Company’s ability to generate income from ongoing business operations.

Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP net income before provision for income taxes, total other (income) expense, stock-based compensation expense, depreciation and amortization, and amortization of purchased intangibles and “Non-GAAP Adjusted EBITDA Margin” as Non-GAAP Adjusted EBITDA as a percentage of total revenue. Management defines “Non-GAAP Adjusted Operating Income” as the sum of GAAP net income before provision for income taxes, total other (income) expense, stock-based compensation expense, and amortization of purchased intangibles, and “Non-GAAP Adjusted Operating Income Margin” as Non-GAAP Adjusted Operating Income as a percentage of total revenue. Management defines “Non-GAAP Adjusted Net Income” as the sum of GAAP net income before (gain) loss on interest rate derivative contract, stock-based compensation expense, amortization of purchased intangibles, and any tax impact related to these items, and “Non-GAAP Adjusted Net Income per Diluted Share” as Non-GAAP Adjusted Net Income divided by weighted average diluted shares outstanding. Management considers all of these non-GAAP financial measures to be important indicators of the Company’s operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company’s overall financial performance.

Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

 

   

Stock-based compensation expense — excluded because these are non-cash expenses that management does not consider part of ongoing operating results when assessing the performance of the Company’s business, and also because the total amount of expense is partially outside of

 

11


 

the Company’s control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to the Company’s performance during the period in which the expense is incurred.

 

   

Amortization of purchased intangibles — purchased intangibles are amortized over their estimated useful life and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Thus, including such charge does not accurately reflect the performance of the Company’s ongoing operations for the period in which such charge is incurred.

 

   

Gains and losses on interest rate derivative contract — excluded because, until they are realized, to the extent these gains or losses impact a period presented, management does not believe that they reflect the underlying performance of ongoing business operations for such period.

 

12